What is the mechanism by which ocrelizumab (ocrelizumab) can transiently improve vision in a patient with rapid‑onset bilateral painless vision loss due to multiple sclerosis, who experiences infusion reactions preventing completion of the dose, and also has a TUBB3 gene mutation?

Transient Vision Improvement: Likely Cytokine-Mediated Inflammatory Modulation

The transient 6-hour vision improvement following incomplete ocrelizumab infusions most likely represents an acute anti-inflammatory effect from cytokine release and immediate immune modulation, rather than therapeutic B-cell depletion, which requires 14 days to occur and would not explain such rapid, short-lived improvement. 1

Mechanism of Transient Effect

Immediate Inflammatory Modulation (Hours)

The rapid vision recovery you're observing occurs far too quickly to be from ocrelizumab's primary mechanism of B-cell depletion. According to the FDA label, CD19+ B-cell counts are reduced by 14 days after administration 1, not within 6 hours. Instead, what's happening is:

• Cytokine release during infusion reactions: Ocrelizumab causes infusion-related reactions in 34-40% of MS patients, with the highest incidence at first infusion 1. These reactions involve cytokine release 2, which paradoxically may have acute anti-inflammatory effects on active CNS inflammation
• Immediate immune cell activation changes: Research shows that ocrelizumab infusion causes "short-lived changes in other immune cell populations in number, activation and cytokine secretion after each OCR infusion" 2
• Corticosteroid premedication effect: The patient receives corticosteroid premedication (typically methylprednisolone or equivalent) 30 minutes before infusion 1, which provides potent anti-inflammatory effects lasting several hours

Why Vision Improves Then Deteriorates

The 6-hour window suggests:

1. Acute inflammatory suppression from the combination of premedication steroids and initial drug exposure
2. Insufficient B-cell depletion because the infusions are incomplete—the therapeutic mechanism requires full dosing to achieve sustained B-cell depletion
3. Rebound inflammation once the acute effects wear off, as the underlying pathology (growing lesions) remains untreated

The Disconnect: Why Lesions Continue Growing

This is the critical issue: The lesions continue to grow because the patient is not receiving therapeutic doses of ocrelizumab. The mechanism requires:

• Complete infusion for adequate drug exposure: After subcutaneous administration of 920 mg, mean Cmax is 132 µg/mL reached after approximately 4 days 1
• Sustained B-cell depletion: The therapeutic effect in MS requires maintaining B-cell depletion over time, not transient exposure 1
• Your patient is getting neither—only brief exposure during failed infusions

TUBB3 Mutation Considerations

The TUBB3 gene mutation adds complexity but doesn't explain the ocrelizumab response pattern. TUBB3 mutations affect neuronal migration and axonal guidance, potentially contributing to:

• Baseline neurological vulnerability
• Atypical MS presentation
• But not the transient response to incomplete ocrelizumab infusions

Clinical Management Algorithm

Immediate Priority: Complete Immunosuppression

Given severe, rapidly progressive bilateral vision loss with growing lesions, this patient needs effective disease control urgently:

1. Rapid desensitization protocol: Case reports demonstrate successful ocrelizumab desensitization in patients with immediate hypersensitivity reactions 3. This should be attempted at a center with expertise in drug desensitization

2. Alternative anti-CD20 therapy: Consider rituximab with desensitization, as it has similar mechanism but different formulation that may be tolerated

3. Alternative high-efficacy DMT if desensitization fails:

   • Alemtuzumab (different mechanism, lymphocyte depletion)
   • Natalizumab (α4-integrin inhibitor)
   • Cladribine (oral lymphocyte-depleting therapy)

4. Bridge therapy while establishing tolerance:

   • High-dose IV methylprednisolone (1g daily × 3-5 days) for acute inflammatory control
   • Consider plasma exchange (PLEX) if steroid-refractory, as recommended for severe demyelinating presentations 4

Diagnostic Verification

Given atypical features (TUBB3 mutation, severe bilateral presentation, infusion reactions):

• Confirm MS diagnosis: Ensure this isn't neuromyelitis optica spectrum disorder (NMOSD) or MOG antibody disease, which can present with severe bilateral optic neuritis 5, 6
• Test for aquaporin-4 and MOG antibodies: These conditions require different treatment approaches
• MRI orbits with and without contrast: To characterize optic nerve involvement 5, 6

Critical Pitfall

Do not continue attempting standard ocrelizumab infusions without desensitization protocol. The transient improvement is misleading—it's not therapeutic benefit, and the patient is accumulating irreversible disability while lesions grow unchecked. The 6-hour vision improvement is essentially a "tease" from acute inflammatory modulation without achieving the sustained B-cell depletion needed for disease control.

The priority is establishing any effective high-efficacy therapy through either successful desensitization or switching to an alternative agent, rather than continuing to chase the transient improvements from incomplete infusions.